British Columbia Medical Assistance in Dying Prescription
|
|
- Eustace Walsh
- 5 years ago
- Views:
Transcription
1 British Columbia Medical Assistance in Dying Prescription Date: Page 1 of 6 Upon completion of MAID: 1) to provide copy of MAR to Pharmacist for reconciling the return of unused and partially used medications in Prescription Accountability section of Prescription; 2) Pharmacist to provide copy of completed Prescription (including Prescription Accountability section) to ; 3) to fax completed Prescription (all sections, including MAR) with all other MAID forms to BC Coroners Service, Attention Deputy Chief Coroner, fax ; 4) For cases involving a health authority (HA), to fax or mail an additional copy of Prescription (all sections) to applicable HA (see bottom of page 4 for HA fax numbers and mailing information); 5) to retain a copy of Prescription (all sections) in patient s health record. Identification and Declaration Patient Information Name: Address: Medical Information (pertinent to medical assistance in dying - allergies, etc.): Medical / Nurse Practitioner Information () Name: CPSID #: CRNBC #: Address: Telephone Number: Signature: Medical / Nurse Practitioner Declaration () The will initial each statement to declare it is true. The Pharmacist will initial the first statement to acknowledge discussion and confirmation with. The intention is NOT that the Pharmacist performs an assessment of the patient s eligibility criteria or obtains consent from the patient these functions are to only be performed by the. I confirm the medications prescribed on this form are intended for the purpose of medical assistance in dying, and patient s drug therapy has been discussed. I have determined the patient is capable to consent to medical assistance in dying. I have determined the patient is suffering from a grievous and irremediable medical condition and meets the eligibility criteria. I have received informed consent from the patient authorizing medical assistance in dying. Name of other Medical / Nurse Practitioner who confirms that the patient meets the eligibility criteria. Pharmacist
2 Intravenous Protocol Administered by Medical / Nurse Practitioner Patient Name: Page 2 of 6 The following are the components of the Medical or Nurse Practitioner-Administered medical assistance in dying intravenous drug protocol. Initial to confirm the selected drug for each protocol component. Sign the form at the bottom to prescribe the selected medications. Indicate by checkmark whether IV Regimen is: midazolam (1 mg/ml) Local Anaesthetic lidocaine (20 mg/ml) Primary IV Kit x 2 (Pharmacist must dispense 2 identical IV kits of all drugs in a sealed / tamperproof container.) or Back-up IV Kit for Oral Regimen Dispensed Quantity Dosage Notes (Mitte) Anxiolytic (Initial to confirm anxiolytic is being ordered.) 10 mg x mg to 10 mg IV over 2 minutes. May repeat additional dose x 1 PRN. midazolam 1 mg/ml is preferred formulation. 40 mg 40 mg IV over 30 seconds. lidocaine 20 mg/ml is preferred formulation. COMA Inducing Agent (CHOOSE one of the two alternatives. Initial to indicate selected agent.) propofol (10 mg/ml) phenobarbital (120 mg/ml) Neuromuscular Blocker rocuronium (10 mg/ml) OR IV Line Flush Solution sodium chloride 0.9% solution 1 g x 1 1 g IV over 5 minutes. May repeat additional dose x 1 PRN. 3 g x 1 sodium chloride 0.9% 10 ml x 3 for injection (for dilution) 3 g (dilute to 50 ml with sodium chloride 0.9%) IV over 5 minutes. May repeat additional dose x 1 PRN. 200 mg 200 mg by rapid IV injection. 1 st line agent Obtain additional PRN from back-up IV kit, if required. 2 nd line agent phenobarbital 120 mg/ml is preferred formulation. Confirm deep medically-induced coma before administration. 10 ml x 6 Flush IV line after each medication to ensure entire dose is given AND to. Medical / Nurse Practitioner Signature () My signature serves to prescribe the medications initialed above for this patient. Signature Date CPSID # or CRNBC #
3 Oral Protocol Self-Administered (Supervised by Medical / Nurse Practitioner) Patient Name: Page 3 of 6 The following are the components of the Self-Administered medical assistance in dying oral drug protocol. Initial to confirm the selected drug(s) for each protocol component. Sign the form at the bottom to prescribe the selected medications. For controlled prescription drugs (e.g. morphine), provide an additional prescription written on a duplicate prescription form and attach to this form. Dispensed Dosage Notes Quantity (Mitte) Gastric Motility / Anti-Emetic metoclopramide 20 mg (tablets) ondansetron 8 mg (tablet) haloperidol 5mg (5 mg/ml) 10 mg tablets x 2 20 mg (2 tablets) orally one hour prior to ingesting comainducing agent. 8 mg tablet x 1 8 mg (1 tablet) orally one hour prior to ingesting comainducing agent. 5 mg intravenous vials x 2 Anxiolytic (Initial to confirm anxiolytic is being ordered.) LORazepam 0.5 mg (sublingual tablets) 0.5 mg sublingual tablets x 8 5 mg subcutaneous or IV over 1 minute PRN for emesis during procedure. May repeat additional dose x 1 PRN. 0.5 mg to 2 mg (1 to 4 tablets) sublingually, 5 to 10 minutes prior to ingesting coma-inducing agent, if needed for anxiety. May repeat additional dose x 1 PRN. COMA Inducing Agent (Initial to confirm each ingredient is being ordered.) Powder Mixture: phenobarbital powder* 20 g Shake well. Ingest the entire prescription in less chloral hydrate powder* 20 g than 4 minutes. morphine sulphate powder** [Note: Omit morphine if patient has significant morphine allergy (i.e. anaphylaxis)] ORA-Plus / ORA-Sweet (50/50) or Distilled Water for feeding tube 3 g qs to 120 ml *Active ingredients required for coma induction. **Optional, depending on patient factors (e.g., adverse effects, tolerance). Stable for 72 hours. Use haloperidol 5 mg/ml intravenous formulation Patient to follow with a small amount of nonfat, non-carbonated drink. If compound is to be administered via PEG or NG tube, replace ORA- Plus /ORA Sweet with 120 ml of water. Flush feeding-tube with 60 to 90 ml of water after medication. Notes: 1) must complete the Intravenous Protocol section of the prescription form to prescribe the specific contents of the back-up IV kit. 2) Pharmacist must dispense 1 po kit plus 1 IV kit as backup in sealed / tamperproof container. The backup IV kit should include a second dispensed quantity of propofol or phenobarbital (i.e., total dispensed quantity of propofol 1 g x 2, or phenobarbital 3g x 2 ). Medical / Nurse Practitioner Signature () My signature serves to prescribe the medications initialed above for this patient. Signature Date CPSID # or CRNBC #
4 Page 4 of 6 Prescription Planning Patient Name: Planned Date and Time of Prescription Release and Return of Unused Medications Planned Release Date (YYYY/MM/DD): Planned Return Date (YYYY/MM/DD): Planned Release Time (00:00 am/pm): Planned Return Time (00:00 am/pm): Plan for Concluding Medical Assistance in Dying Process Procedures have been established for the return of any unused and partially used medication(s) within 48 hours to the Pharmacy for secure and timely disposal. Any Pharmacist within the dispensing pharmacy can receive back unused and partially used medications from the. Completed Prescription Accountability Medication Administration Record The has been instructed on how to complete the Medication Administration Record for medical assistance in dying medications. Dispensing Sign-Off Completed Printed Name Signature College ID Date Time Dispensed by: (Pharmacist) Received by: () CPBC License #: CPSID # / CRNBC #: Confirmation of photo ID of, if applicable: Completed Return of All Unused and Partially Used Medications to Pharmacist for Disposal The will return all unused and partially used medications to the pharmacy within 48 hours of the patient s death. The Pharmacist will reconcile and document the return of unused and partially used medication(s) below. Medication Name(s) Form Strength Quantity Printed Name Signature College ID Date Time Returned by: () Received by: (Pharmacist) CPSID # / CRNBC #: CPBC License #: Health Authority fax numbers for submission of forms: For mailing addresses of Health Authorities, FHA: Fax: NHA: Fax: VIHA: Fax: see Document Submission Checklist, HLTH IHA: Fax: VCHA: Fax: PHSA: Fax:
5 Page 5 of 6 Medication Administration Record (Provide copy of completed MAR to Pharmacist) Medical Assistance in Dying Intravenous Protocol (Administered by Medical / Nurse Practitioner) Date: Name of Patient: PHN: Name of Medical / Nurse Practitioner (): CPSID #: CRNBC #: Signature: : Dose Administered Time Given Anxiolytic midazolam 2.5 to 10 mg IV over 2 minutes Anesthetic lidocaine 40 mg IV over 30 seconds Coma-inducing Agent - Choose propofol OR phenobarbital propofol 1 g IV over 5 minutes phenobarbital 3 g (dilute to 50 ml with sodium chloride 0.9%) IV over 5 minutes Neuromuscular Blocker Confirm patient is in deep medically-induced coma* prior to administration rocuronium 200 mg by rapid IV injection * Deep medically-induced coma: No response to verbal stimuli, unable to rouse; serious depression of circulation, evidenced by weak pulse; serious depression of ventilation, evidenced by slow, shallow breathing; no protective reflexes, such as eyelash reflex.
6 Page 6 of 6 Medication Administration Record (Provide copy of completed MAR to Pharmacist) Medical Assistance in Dying Oral Protocol (Supervised by Medical / Nurse Practitioner) Date: Name of Patient: PHN: Name of Medical / Nurse Practitioner (): CPSID #: CRNBC #: Signature: : Dose Administered Time Given Anti-emetic (prior to procedure) metoclopramide 20 mg (10 mg tablets x 2) 1 hour prior to the coma-inducing agent ondansetron 8 mg (1 tablet) 1 hour prior to coma-inducing agent Anxiolytic LORazepam 0.5 mg sublingual tablets 0.5 to 2 mg (1 to 4 tablets), 5 to 10 minutes prior to coma-inducing agent, as needed for anxiety Coma-inducing Agent phenobarbital powder 20 g chloral hydrate powder 20 g morphine sulphate powder 3 g (cross-out morphine, if not given) ***Shake well. *** Ingest entire mixture in less than 4 minutes, followed by a glass of water or non-carbonated, non-fat liquid of patient s choice. For PEG or NG tube administration, flush feeding-tube with 60 to 90 ml of water after medication. Anti-emetic (during procedure) haloperidol 5 mg SUBCUT or IV over 1 minute as needed for emesis
Medical Assistance in Dying (MAID) Pharmacy Protocols Aug 16, 2016 Developed in partnership with:
Medical Assistance in Dying (MAID) Pharmacy Protocols Aug 16, 2016 Developed in partnership with: The Alberta College of Pharmacists The Alberta College of Physicians and Surgeons Alberta Health 1 Table
More informationPHARMACY SERVICE ARRANGEMENTS FOR THE SUPPLY OF PALLIATIVE CARE SYRINGES AND MEDICINES FOR COMMUNITY PATIENTS
PHARMACY SERVICE ARRANGEMENTS FOR THE SUPPLY OF PALLIATIVE CARE SYRINGES AND MEDICINES FOR COMMUNITY PATIENTS The benefits of prefilled syringes for palliative care from the hospital pharmacy service In
More informationAdministration of Medication
Administration of Medication Prescribed medications must arrive in a container with the original, unaltered prescription label attached. The label must display all legal information required for a pharmacist
More informationThe Oral MAiD Option in Canada Part 2: Processes for Providing. Review and Recommendations
The Oral MAiD Option in Canada Part 2: Processes for Providing Review and Recommendations Harty C, Chaput AJ, Buna D, Trouton K, & Naik VN A Canadian Association of MAiD Assessors and Providers (CAMAP)
More informationFREQUENTLY ASKED QUESTIONS PHARMACISTS
FREQUENTLY ASKED QUESTIONS PHARMACISTS Q. Why did the College update standards for methadone maintenance treatment (MMT)? A. The College updated standards for MMT in collaboration with PharmaCare and other
More informationPPP 1. Continuation, modification, and discontinuation of a medication
PRESCRIBING POLICIES: 4.7 PHARMACIST AUTHORITY The College of Pharmacists of BC Professional Practice Policy (PPP) 58 Medication Management (Adapting a Prescription) became effective April 1, 2009. The
More informationPolicy Guide Injectable Hydromorphone Maintenance Treatment (2018)
Professional Practice Policy #67 Policy Guide Injectable Hydromorphone Maintenance Treatment (2018) P2 Injectable Hydromorphone Maintenance Treatment Policy Guide All pharmacy managers, staff pharmacists,
More informationAlgorithms for Symptom Management. In End of Life Care
Algorithms for Symptom Management In End of Life Care The Use of Drugs Beyond Licence (off label) -The Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK regulates the activity of the
More informationCare in the Last Days of Life
Care in the Last Days of Life Introduction This guideline is an aid to clinical decision making and good practice in person-centred care for patients who are deteriorating and at risk of dying. The patient
More informationSedation in Children
CHILDREN S SERVICES Sedation in Children See text for full explanation and drug doses Patient for Sedation Appropriate staffing Resuscitation equipment available Monitoring equipment Patient suitability
More informationAPIDRA (insulin glulisine) injection vial APIDRA SOLOSTAR (insulin glulisine) subcutaneous solution pen-injector
APIDRA SOLOSTAR (insulin glulisine) subcutaneous solution pen-injector Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationManaging Your Pain After Day Surgery
Managing Your Pain After Day Surgery Information for patients and families UHN Read this information to learn why it s important to manage your pain how to control your pain when you get home side effects
More informationSEVERE ALLERGY/ANAPHYLAXIS ACTION PLAN & TREATMENT AUTHORIZATION Appendix F-4A
PART I - TO BE COMPLETED BY PARENT Student Date of Birth Teacher/Grade Allergy Route of Exposure Contact Ingestion Weight lbs. Inhalation Sting Asthmatic Yes* No *Higher risk for severe reaction Parent
More informationReferral Forms for TYVASO and REMODULIN
Referral Forms for TYVASO and REMODULIN HOW TO GET STARTED Tyvaso and Remodulin are available only through select Specialty Pharmacy Services (SPS) providers. Follow these 5 simple steps to complete each
More informationThis document is to help guide the use of the provided GRH IV Iron Sucrose package. The documents included in the IV Iron Sucrose Package are:
This document is to help guide the use of the provided GRH IV Iron Sucrose package. The documents included in the IV Iron Sucrose Package are: 1. Adult Outpatient Iron Sucrose Order set (page 2 and 3)
More informationNHS Grampian Staff Guidance For The Management Of Hypomagnesaemia In Adults. Consultation Group: See Page 4. Review Date: June 2021
NHS...... Grampian NHS Grampian Staff Guidance For The Management Of Hypomagnesaemia In Adults Co-ordinators: Consultation Group: Approver:. Senior Medicines Information Pharmacist See Page 4 Medicine
More informationPackage leaflet: Information for the patient. NEGABAN 1g, powder for solution for injection or infusion Temocillin
Package leaflet: Information for the patient NEGABAN 1g, powder for solution for injection or infusion Temocillin Read all of this leaflet carefully before you start using this medicine because it contains
More informationResearch Implementation Office (RIO) Solid Tumor/Heme/Heme Malignancy Protocol Specific Pre printed Order (PPO) Guidelines
Research Implementation Office Solid Tumor/Heme/Heme Malignancy Protocol Specific Pre printed Order (PPO) Guidelines Note: As of February 11, 2015, the only preprinted orders which remain on paper for
More informationThe only sublingual grass allergy immunotherapy tablet with a mixed pollens allergen extract from 5 grasses 1
The only sublingual grass allergy immunotherapy tablet with a mixed pollens allergen extract from 5 grasses 1 An important immunotherapy option for patients with grass allergies Effective during the first
More informationMethadone/Buprenorphine Prescriptions
Methadone/Buprenorphine Prescriptions From office to pharmacy to patient Joy Bhimji BSP Methadone/Buprenorphine 101 Workshop December 10, 2016 Which prescription (Rx)? Suboxone write in DWI, carry info
More informationMedication Safety Presentation
Appendix E Aid 1: Sample Event Poster Medication Safety Presentation Do YOU know your role on the healthcare team? Do YOU know the questions to ask your pharmacist? Do YOU know safe medication practices?
More informationINFORMATION FOR FILLING OUT APPLICATION FORM FOR AN EXEMPTION TO USE A CONTROLLED SUBSTANCE FOR SCIENTIFIC PURPOSES (a Health Canada document)
INFORMATION FOR FILLING OUT APPLICATION FORM FOR AN EXEMPTION TO USE A CONTROLLED SUBSTANCE FOR SCIENTIFIC PURPOSES (a Health Canada document) Quote from Health Canada website: http://www.hc-sc.gc.ca/hc-ps/substancontrol/exemptions/index-eng.php
More informationAdministration and Supply of Emergency Medicines
APPENDIX WHO CAN GIVE WHAT? Administration and Supply of Emergency Clinician Authorisation Key to Exemptions from legislation: NPP Non Parenteral POM. Can be given according to a protocol. 7 HMR 0, Schedule
More informationFor patients and their carers this means smoother symptom control, better support in a crisis, and avoidance of admission if that is their choice.
Bedfordshire Palliative Care Palliative Care Medicines Guidance This folder has been produced to support professionals providing palliative care in any setting. Its aim is to make best practice in palliative
More informationContributes to CQC Outcome number: 9&12 Consulted With Post/Committee/Group Date. Pharmacist. Alison Felton Head of Pharmacy/Deputy Chief.
Prescribing paracetamol in adult inpatients at MEHT Type: Clinical Guideline Register No: 18005 Status: Public on ratification Developed in response to: In line with Basildon Contributes to CQC Outcome
More informationCONTINUATION OF IMMUNOTHERAPY INJECTIONS AT RIDER UNIVERSITY ALLERGIST INFORMATION AND PERMISSION FORM
CONTINUATION OF IMMUNOTHERAPY INJECTIONS AT RIDER UNIVERSITY ALLERGIST INFORMATION AND PERMISSION FORM Dear Allergist: Your patient,, would like to continue allergy injections in our health center while
More informationModule 8: Practice Problems
Module 8: Practice Problems 1. Convert a blood plasma level range of 5 to 20 µg/ml of tobramycin (Z = 467.52) to µmol/l. 5 µg/ml = 10.7 µmol/l 20 µg/ml = 42.8 µmol/l 2. A preparation contains in each milliliter,
More informationAttach patient label here. Physician Orders ADULT: Palliative Care Plan
Initiate Orders Phase Care Sets/Protocols/PowerPlans Initiate Powerplan Phase T;N, Phase: Palliative Care Phase, When to Initiate: Palliative Care Phase Admission/Transfer/Discharge Patient Status Initial
More informationPackage leaflet: Information for the user
Package leaflet: Information for the user Cisatracurium 2 mg/ml Solution for injection/ infusion Cisatracurium 5 mg/ml Solution for injection/ infusion Cisatracurium The name of your medicine are Cisatracurium
More informationAccess to Palliative Care Drugs and Advice through Lothian Primary Care NHS Trust Community Pharmacy Palliative Care Network
Access to Palliative Care Drugs and Advice through Lothian Primary Care NHS Trust Community Pharmacy Palliative Care Network Information for GPs, community pharmacists and district nurses First issued
More informationMidazolam Injection Midazolam
Midazolam Injection Midazolam Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about Midazolam Injection. It does not contain all the available information.
More informationMethadone 8.3. Dispensing (Ontario) This document describes the recommended way to setup and dispense Methadone mixtures.
Methadone 8.3 Dispensing (Ontario) This document describes the recommended way to setup and dispense Methadone mixtures. Last Updated: February 15, 2010 Table of Contents Methadone Drug and Mixture Card
More informationIMPORTANT: PLEASE READ
PART III: CONSUMER INFORMATION ALPROLIX [pronounced all prō liks] Coagulation Factor IX (Recombinant), Fc Fusion Protein This leaflet is part III of a three-part "Product Monograph" published when ALPROLIX
More informationPATIENT GROUP DIRECTION (PGD)
PATIENT GROUP DIRECTION (PGD) SUPPLY OF NALOXONE HYDROCHLORIDE INJECTION BY REGISTERED NURSES TO CLIENTS BEING RELEASED FROM HMP FORD Version Number: 01HMP Patient Group Direction originally drawn up by:
More informationDrug Prescription and Administration Record
Chart No. this admission Drug Prescription and Administration Record Patient s Name: of Admission: Chart Start : Chart Finish : NHS No: Consultant Code: Ward: ALERT: of Birth: ADDITIONAL CAUTIONS FOR PRESCRIBING
More informationHazardous Materials Medication Box and Exchange Procedure
September 2012 Page 1 of 6 Hazardous Materials Medication Box and Exchange Procedure EMS Service Stock 1. Each EMS Agency will be responsible for the security and storage of the supply of hazardous material
More informationHazardous Materials Medication Box and Exchange Procedure
May 2017 Page 1 of 5 Hazardous Materials Medication Box and Exchange Procedure EMS Service Stock 1. Each EMS Agency will be responsible for the security and storage of the supply of hazardous material
More informationSedation in children and young people. Appendix J. Sedation for diagnostic and therapeutic procedures in children and young people
SEDATION IN CHILDREN AND YOUNG PEOPLE 1 Sedation in children and young people Sedation for diagnostic and therapeutic procedures in children and young people Appendix J 2 SEDATION IN CHILDREN AND YOUNG
More informationUser Guide for Transition to the Drug Information System
User Guide for Transition to the Drug Information System Document Revision History Date Description Version Updated By August 12, 2013 New/revised content 1.0 Lori Emery Version 1.0 Page 2 of 13 Table
More informationOpioids in the Community: Chronic pain, Palliative Care, and Addiction. Dr Ahmed Jakda September 2017
Opioids in the Community: Chronic pain, Palliative Care, and Addiction Dr Ahmed Jakda September 2017 Outline Context Background Action Delisting Highstrength Long- Acting Opioids Opioid use and prescribing
More informationIntravenous Immunoglobulin (IVIg) prescribing guidance
Intravenous Immunoglobulin (IVIg) prescribing guidance Kejal Mehta (Specialist Pharmacist) [December 2016] Review Date: December 2017 Contents Introduction:... 2 Prior to Intravenous immunoglobulin (IVIg)
More informationCare of the Dying. For dosing in severe renal impairment see separate guidance for care of the dying in severe renal failure.
Care of the Dying Early diagnosis of the dying process allows for adequate preparation of the patient, the family and the carers. This clinical guidance covers the prescribing and management of patients
More informationHelp Prevent Medication Errors with PDC Healthcare s Anesthesia Labels & Tapes
Help Prevent Medication Errors with PDC Healthcare s Anesthesia Labels & Tapes Where positive identification meets safe, efficient patient care. Improve Patient Safety with Accurate Medication Labeling
More informationLEVEMIR (insulin detemir) subcutaneous solution LEVEMIR FLEXTOUCH (insulin detemir) subcutaneous solution pen-injector
LEVEMIR FLEXTOUCH (insulin detemir) subcutaneous solution pen-injector Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationRead all of this leaflet carefully before you are given this medicine because it contains important information for you.
[Aspen] Package Leaflet: Information for the Patient Ultiva for injection remifentanil hydrochloride Read all of this leaflet carefully before you are given this medicine because it contains important
More informationKetorolac injection. Supportive care
Supportive care Ketorolac injection Supportive care: specialist medicines This leaflet provides information on a medicine called ketorolac which is used to treat pain that is difficult to control. It is
More informationPackage Leaflet: Information for the User Zotron 4mg/2ml (ή 8mg/4ml) Solution for Injection or Infusion ondansetron
Package Leaflet: Information for the User Zotron 4mg/2ml (ή 8mg/4ml) Solution for Injection or Infusion ondansetron Read all of this leaflet carefully before you start taking this medicine because it contains
More informationCompounding KI for Radiation Exposure
PL Detail-Document #270323 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER March 2011 Compounding KI for
More informationADULT Updated: September 4, 2018
Updated: September 4, 2018 Regimen Reference Order ARIA: LYMP [R-CHOP alt. R-DHAP] Planned Course: Indication for Use: Every 21 days for 6 cycles (R-CHOP given on cycles 1, 3 and 5; R-DHAP given on cycles
More informationAdministering Medicines to Students Asthma Inhaler Exemption
Administering Medicines to Students Asthma Inhaler Exemption Any school employee authorized in writing by the district administrator or school principal: 1. May assist in the self-administration of any
More informationPAEDIATRIC DOSAGE GUIDELINES For management of post-operative acute pain
Index No: MMG43 PAEDIATRIC DOSAGE GUIDELINES For management of post-operative acute pain Version: 3.1 (Includes anti-emetics and naloxone) Date ratified: July 2013 Ratified by: (Name of Committee) Name
More informationControlled Drugs Accountable Officers Network Scotland Executive Group. Gabapentin and Pregabalin - Frequently Asked Questions
Gabapentin and Pregabalin - Frequently Asked Questions Gabapentin and pregabalin will become Schedule 3 Controlled Drugs in April 2019 NHS Contractor Services Prescribers are legally permitted to be in
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Cisatracurium 2 mg/ml solution for injection/infusion Cisatracurium 5 mg/ml solution for injection/infusion
PACKAGE LEAFLET: INFORMATION FOR THE USER Cisatracurium 2 mg/ml solution for injection/infusion Cisatracurium 5 mg/ml solution for injection/infusion Cisatracurium Read all of this leaflet carefully before
More informationRegulations: Adult Minimal Sedation
Regulations: Adult Minimal Sedation Jason H. Goodchild, DMD DrGoodchild@yahoo.com April 2017 Regulations Caveats 1. The regulations about to be presented are accurate and current as of today. 2. This could
More informationA step-by-step preparation guide
A step-by-step preparation guide For needle and needle-free systems This guide provides detailed instructions on the reconstitution, dilution, and storage of VELETRI. It is intended to be used after your
More informationDispensing and administration of emergency opioid antagonist without a
68-7-23. Dispensing and administration of emergency opioid antagonist without a prescription. (a) A pharmacist may dispense an FDA-approved emergency opioid antagonist and the necessary medical supplies
More informationBC OPIOID SUBSTITUTION TREATMENT SYSTEM Performance Measures 2012/2013
BC OPIOID SUBSTITUTION TREATMENT SYSTEM Performance Measures 212/213 Office of the Provincial Health Officer With contributions by: Medical Beneficiary & Pharmaceutical Services Division & Population and
More informationSafe Medication Use. Patient Teaching Slides
Safe Medication Use Patient Teaching Slides 3 Ways to Improve Medication Safety 1. Talk to your Doctor or Pharmacist about Your Medications 2. Organize, Store, Secure, and Dispose of Your Medications Safely
More informationIMPORTANT: PLEASE READ
PART III: CONSUMER INFORMATION ALPROLIX [pronounced all prō liks] Coagulation Factor IX (Recombinant), Fc Fusion Protein This leaflet is part III of a three-part "Product Monograph" published when ALPROLIX
More informationPackage leaflet: Information for the user
Package leaflet: Information for the user Lartruvo 10 mg/ml concentrate for solution for infusion olaratumab This medicine is subject to additional monitoring. This will allow quick identification of new
More informationEvidence-Based Clinical Practice Guideline. Treatment & Management of Ocular Disease
Evidence-Based Clinical Practice Guideline Treatment & Management of Ocular Disease Effective November 29, 2017 Treatment & Management Of Ocular Disease Clinical Practice Guideline The objective of this
More informationUnit 204 Assist with the assembly of prescribed items
Element 1 Assemble prescribed 171 172 Element 1 Assemble prescribed Background Assembling prescribed is a complex process. The two main components of this process are labelling and dispensing. It is essential
More informationNaloxone and Combating the Opioid Epidemic
Objectives Naloxone and Combating the Opioid Epidemic Jeff Jacobson PharmD Southpointe Pharmacy Discuss the current opioid crisis Define the role of Naloxone in opioid overdose Analyze the barriers to
More informationMIDAZOLAM APOTEX Solution for Injection Contains the active ingredient midazolam
MIDAZOLAM APOTEX Solution for Injection Contains the active ingredient midazolam Consumer Medicine Information For a copy of a large print leaflet, Ph: 1800 195 055 What is in this leaflet Read this leaflet
More informationGuidance for Industry DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.
Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance for Industry DRAFT GUIDANCE This guidance
More informationPolicy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04
Policy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04 Date issued Issue 1 Nov 2018 Planned review Nov 2021 PPT-PGN 18 part of NTW(C)38 Pharmaceutical
More informationPHYSICIAN ORDER SET : Patient: DOB: Gender: Patient Phone #: Height: Weight:
. (Patient Sticker) CDH 208-203 Approved 2/18 - Page 1 of 5 Patient: DOB: Gender: Patient Phone #: Height: Weight: Diagnosis: ICD-10 Code: Treatment Start Date: Provider Facility Name: Ordering Provider:
More informationCHEMOTHERAPY NETWORK GROUP POLICY FOR ADMINISTRATION OF CYTOTOXIC CHEMOTHERAPY
CHEMOTHERAPY NETWORK GROUP POLICY FOR ADMINISTRATION OF CYTOTOXIC CHEMOTHERAPY Version 4.0 March 2016 Review date March 2018 Introduction It is the purpose of this policy to provide clear guidelines that
More informationDUKORAL. Oral inactivated cholera and ETEC vaccine. Consumer Medicine Information. It does not take the place of talking to your doctor or pharmacist.
What is in this leaflet DUKORAL Oral inactivated cholera and ETEC vaccine Consumer Medicine Information This leaflet answers some common questions about Dukoral. It does not contain all the available information.
More informationMedication Safety. Patient Safety. Setting Direction Julie Simmons, Medication Safety Pharmacist January 2016
Medication Safety Patient Safety Setting Direction Julie Simmons, Medication Safety Pharmacist January 2016 1 The patient journey Admission Ward Transfer Ward stay Discharge Medication storage and supply
More informationArtesunate 60 mg for injection WHOPAR part 3 June 2013 (Guilin Pharmaceutical Co., Ltd.), MA051 PATIENT INFORMATION LEAFLET
PATIENT INFORMATION LEAFLET 1 PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER Artesun * Artesunate 60 mg for injection and sodium bicarbonate injection 50 mg/ml (1ml) and sodium chloride injection
More informationNova Scotia Drug Information System
Nova Scotia Drug Information System Functions Presentation Details: Slides: 19 Duration: 00:32:04 Filename: DIS Module4.Functions.ppt Presenter Details: Slide 1 Nova Scotia Drug Information System Duration:
More informationFor further copies of this leaflet, visit emc.medicines.org.uk or call Aspen on +44 (0) Package leaflet: Information for the user
For further copies of this leaflet, visit emc.medicines.org.uk or call Aspen on +44 (0)1 748 828 391. Package leaflet: Information for the user Diprivan 10 mg/ml (1%) Emulsion for Injection or Infusion
More informationAppendix 3: Taking controlled and prescription drugs to other countries
Appendix 3: Taking controlled and prescription drugs to other countries Some patients receiving palliative care travel to other countries and they will need to take their medicines with them. Practitioners
More informationSECTION PRESCRIPTIONS
SECTION.1800 - PRESCRIPTIONS 21 NCAC 46.1801 EXERCISE OF PROFESSIONAL JUDGMENT IN FILLING PRESCRIPTIONS (a) A pharmacist or device and medical equipment dispenser shall have a right to refuse to fill or
More informationIntroduction. Guidelines for patient involvement in the administration of insulin under supervision in hospital (Adult patients)
Guidelines for patient involvement in the administration of insulin under supervision in hospital (Adult patients) Introduction This guideline is designed to provide a framework for patients to administer
More informationNaloxone HCI 4 mg/0.1. nostril. Repeat after 3 minutes if minimal or no
THE SOUTH CAROLINA BOARD OF MEDICAL EXAMINERS AND THE SOUTH CAROLINA BOARD OF PHARMACY S JOINT PROTOCOL TO INITIATE DISPENSING OF NALOXONE HCI WITHOUT A PRESCRIPTION This joint protocol authorizes any
More informationControlled Substance Prescribing: A Physician s Guide. Bethanie Gamble, PharmD Department of Pharmacy Greenville Health System
Controlled Substance Prescribing: A Physician s Guide Bethanie Gamble, PharmD Department of Pharmacy Greenville Health System Objectives Review schedules of controlled substances and their propensity for
More informationGood Practice Guidance on Covert Administration of Medication
Good Practice Guidance on Covert Administration of Medication This good practice guidance is intended to be used as a framework for care home managers and domiciliary care providers in drawing up their
More informationPain & Sedation Management in PICU. Marut Chantra, M.D.
Pain & Sedation Management in PICU Marut Chantra, M.D. Pain Diseases Trauma Procedures Rogers Textbook of Pediatric Intensive Care, 5 th ed, 2015 Emotional Distress Separation from parents Unfamiliar
More informationDear Parent or Guardian,
Dear Parent or Guardian, This summer may be a period of transition for you and your child. For a lot of our students it may even be the first time they are taking the lead in their personal care, including
More informationSYRINGE DRIVER MEDICATIONS
SYRINGE DRIVER MEDICATIONS Christine Hull & Anita Webb Staff Nurses, Hospice in the Home 2015 Analgesics:- Groups of Medication used in Syringe Drivers Morphine sulphate Diamorphine Oxycodone Alfentanil
More information2. Receive the Guidelines for the Allergist letter which is to be given to the prescribing allergist physician.
POLICY: Name of Policy Allergy Immunotherapy Section Clinical Records and Health Information Date Effective January 20, 2005 Date Last Reviewed June 21, 2017 Responsible for Review UCF SHS Director Approved
More informationHome Care Services HomeMed MedEQUIP Michigan Visiting Care Michigan Visiting Nurses Wheelchair Seating Service PROCEDURE
UNIVERSITY OF MICHIGAN HOSPITALS AND HEALTH CENTERS UMHHC-HCS: 253.054 First Approved Date: 3/2010 Home Care Services HomeMed MedEQUIP Michigan Visiting Care Michigan Visiting Nurses Wheelchair Seating
More informationURGENT UPDATED ADVICE ON DOSAGE OF OSELTAMIVIR IN CHILDREN UNDER ONE YEAR OF AGE WITH SWINE FLU
Primary and Community Care Directorate Pharmacy Division T: 0131-244 2518 F: 0131-244 2375 E: bill.scott@scotland.gsi.gov.uk 25 September 2009 abcdefghijklmnopqrstu = 1. Medical Directors NHS Boards 2.
More informationAripiprazole Long-Acting Injection (Abilify Maintena ) Guidelines for Prescribing and Administration (Version 3 August 2014)
1. Key Points. Aripiprazole Long-Acting Injection (Abilify Maintena ) Guidelines for Prescribing and Administration (Version 3 August 2014) 1.1 Aripiprazole long acting injection (LAI) is licensed / indicated
More informationAgency 71. Kansas Dental Board (Authorized by K.S.A and (Authorized by K.S.A and
Agency 71 Kansas Dental Board Articles 71-4. CONTINUING EDUCATION REQUIREMENTS. 71-5. SEDATIVE AND GENERAL ANAESTHESIA. 71-11. MISCELLANEOUS PROVISIONS. Article 4. CONTINUING EDUCATION REQUIREMENTS 71-4-1.
More informationRenal Palliative Care Last Days of Life
Renal Palliative Care Last Days of Life Introduction This guideline is an aid to clinical decision-making and good practice for patients with stage 4-5 chronic kidney disease (egfr
More informationBC OPIOID SUBSTITUTION TREATMENT SYSTEM Performance Measures 2014/ /2016
BC OPIOID SUBSTITUTION TREATMENT SYSTEM Performance Measures 2014/2015-2015/2016 Office of the Provincial Health Officer With contributions by: Medical Beneficiary & Pharmaceutical Services Division &
More informationGuidance on Bulk Prescribing for Care Home Patients
Guidance on Bulk Prescribing for Care Home Patients Introduction Many patients in care homes taking medicines when required (PRN) can inevitably present problems for the prescriber in determining the quantity
More informationPaediatric Prescribing Pocket Guide September 2014 (Version 1)
PAGE 1 Paediatric Prescribing Pocket Guide September 2014 (Version 1) In children, the risk of medication errors is often exacerbated by the need for calculations to determine the dose. Prescribing errors
More informationPackage leaflet: Information for the patient. ROBAXIN mg Film-coated tablets for oral use Methocarbamol. 100 Tablets
Package leaflet: Information for the patient ROBAXIN - 750 750 mg Film-coated tablets for oral use Methocarbamol 100 Tablets Dosage: 2 tablets to be swallowed 4 times a day or as directed by your doctor.
More information1. A patient receives the wrong drug (ex. verified Amox 875 drug dispensed should have been Augmentin 875)
July 12, 2018 Topic: Errors and Omissions Medications errors are made everyday. It is the job of the Pharmacist to prevent these errors from occurring. The right drug to the right patient at the right
More information1. What Octostim Nasal Spray is and what it is used for
Package Leaflet: Information for the User Octostim 1.5 mg/ml Nasal Spray Desmopressin acetate Read all of this leaflet carefully before you start using this medicine because it contains important information
More informationUMC Health System Patient Label Here. PHYSICIAN ORDERS Diagnosis
Diagnosis Weight Allergies Patient Care Vital Signs Per Unit Standards q12h q12h, Temperature Only - Every Shift and PRN Patient Activity Assist as Needed, Bed Position: As Tolerated, elevate to patient
More informationChapter 2 is a general introduction to the drug administration
Chapter 2 Safe and Accurate Drug Administration Chapter Overview Chapter 2 is a general introduction to the drug administration process. It introduces the student to the role of the person who administers
More informationPATIENT INFORMATION LEAFLET. MIDORYX (MIDAZOLAM INJECTION 5mg, 10mg BP)
PATIENT INFORMATION LEAFLET MIDORYX (MIDAZOLAM INJECTION 5mg, 10mg BP) Read all of this leaflet carefully before you start using this medicine. Keep this leaflet. You may need to read it again. If you
More informationSafe Prescribing of Drugs with Potential for Misuse/Diversion
College of Physicians and Surgeons of British Columbia Safe Prescribing of Drugs with Potential for Misuse/Diversion Preamble This document establishes both professional standards as well as guidelines
More informationArtesunate 60 mg for injection WHOPAR part 3 November 2015 (Guilin Pharmaceutical Co., Ltd.), MA051 PATIENT INFORMATION LEAFLET
PATIENT INFORMATION LEAFLET 1 PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER Artesun 60mg * Artesunate 60 mg for injection and sodium bicarbonate injection 50 mg/ml (1ml) and sodium chloride injection
More informationPackage leaflet: Information for the patient. Konakion MM Ampoules 10mg/ml solution for injection and oral solution Phytomenadione (vitamin K 1 )
Package leaflet: Information for the patient Konakion MM Ampoules 10mg/ml solution for injection and oral solution Phytomenadione (vitamin K 1 ) Roche Read all of this leaflet carefully before you start
More information